🔗 Share this article

As the US undertakes unprecedented revisions to its immunization schedules, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccinations in the global health crisis and has concentrated on possible fatalities after Covid immunization in her brief time at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Schedule

Agency leaders had intended to unveil major revisions to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US out of step with a large portion of the international standard with little proof for improved outcomes. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Dr. Høeg is set to address the audience at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to lead the center this year.

Consolidating Power at the FDA

The acting appointment may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling long-standing vaccines at the FDA.

Høeg has frequently advocated for discontinuing specific childhood immunization guidelines in the US to become more similar to Denmark's approach, a society with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s CBER – rather than medication approval.

Doubts Over Qualifications

Dr. Høeg has no apparent experience in drug development, approval processes or administrative roles, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous directors of CBER would “grasp regulatory frameworks and the science of medication creation”, said a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that prior appointees who led the center have had.”

This division has an vast range of responsibilities at the FDA, she pointed out.

“The public just focuses on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic medications. There’s a biologic copycat branch, over-the-counter program and so forth, and each of these need to be supervised,” Woodcock said. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant management element to the position, which manages in excess of 5,000 personnel. “It’s a huge management job, if you do it right,” Woodcock concluded.

Response and Disputed Policies

Regarding concerns about Dr. Høeg's fitness for the role and whether this selection indicates increased cooperation among FDA leaders on vaccines, a spokesperson said that the “concerns stem from incorrect presumptions”.

“Her experience aligns with the responsibilities of her role,” the representative stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg inherits the commissioner’s new expedited review system, a controversial one-day drug-approval program that reportedly worried her former heads. “By what process are these medications being picked for this fast-track system? Who is making the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards laxer oversight of most medications, with the exception of shots.”

Public Past Work on Vaccines

With immunizations, Høeg has a clearer, if problematic, history, some experts have noted. She published a study using unverified volunteer-provided data to estimate the frequency of myocarditis following COVID-19 vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Part of her “desired changes” for the new administration encompassed altering rules for recently developed shots and discontinuing “optional” immunizations, she stated after the election on a audio program. At the agency, Høeg has allegedly suggested excluding young men from getting Covid vaccinations.

“She is an all-around true believer who starts off with her preconceived notions and works backwards to accommodate the evidence in a highly deceptive, fraudulent way,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|